Development of novel sortilin targeted small molecules for more efficient treatment of aggressive breast cancer

Important results from the project

Sortina Pharma AB´s objective is to develop a unique treatment for patients with metastatic breast cancer who do not respond to existing treatments. With these project funds, we wanted to develop our small molecule programme and synthesize new unique molecules with higher potency. Through Vinnova´s funds, we have synthesized a number of new molecules, which has significantly improved our development of small molecules. We are now in a situation where our leading molecules will be validated and optimized and eventually arrive as a drug candidate.

Expected long term effects

Through this Vinnova fund, we have synthesized 7 unique molecules and received answers to 7 unknown SAR questions. This has led to increased SAR understanding and the development of improved molecules that will now be validated and optimized during a lead generation and optimization program to finally reach a drug candidate.

Approach and implementation

The project had 7 well-defined SAR questions that would answer important synthesis questions to develop potent small molecules within the breast cancer indication. Through synthesis of new molecules, these SAR questions could be answered and new unique molecules with higher potency were developed, which significantly brought the project closer to a drug candidate.